Bifidobacterium breve a1 supplementation improved cognitive decline in older adults with mild cognitive impairment: an open-label, single-arm study

Objectives We previously reported the therapeutic potential of Bifidobacterium breve A1 (B. breve A1) for preventing cognitive impairment in Alzheimer’s disease model mice, which suggested that supplementation of the probiotics could be an effective therapeutic strategy for managing cognitive function in mild cognitive impairment (MCI).